Norwegian ISP Altibox chooses Alinto's secure email platform to provide messaging services to its clients
Norwegian ISP Altibox has decided to outsource its email platform to Alinto, with the aim of modernising its messaging services for 180 000 clients in the Nordics. The services provided are based on the SOGomail server and the Cleanmail security service, hosted by Alinto. This move happens a few months after the takeover of the SOGo open-source project by Alinto. It confirms the editors’ ability to address projects on an international scale and cover the whole email chain with GDPR-compliant solutions.
Modernisation of an email platform used by 180 000 clients
Until 2022, Altibox had a messaging platform built and operated in-house. As that platform started to require extensive maintenance operations, Altibox had to move to a new solution.
"We had two options : discontinue the service and delete all the emails – which was not acceptable from a client standpoint, or outsource our email services as we did not have any internal resources to create a new solution”, Marius Ekeland explains.
Thus, the company, which provides email services to 180 000 clients, decided to outsource to an external provider. “Email service is not our core business. We just need to deliver it in the correct way, with a secure manner”, Thomas Lunde adds.
Aligned on features, datacenter compliance and ecological expectations
After issuing an RFP, Altibox chose Alinto's solutions. The services provided are based on the SOGomail server and Cleanmail security service hosted by Alinto. The ISP appreciated the simplicity of the product and the operational stability of the Alinto solution. “Their package provides the best value for us, as it includes insights and access to support as well as an administration portal. This would give us the visibility we needed to properly run the service.
Also, the data centers’ locations are GDPR-compliant and have high ecological expectations. That is essential for us”, Thomas Lunde notes.
Meeting security and migration expectations
Security is of primary importance for Altibox. “The Cleanmail functionality is a big bonus for us because we are constantly strengthening the security of our services as an ISP. So, that matched our strategy”, Markus Ekeland confirms.
Migration of existing mailboxes was a big challenge with 180 terabytes of data to migrate. During migration Alinto’s teams came on-site. “The technical migration went smoothly. We migrated compressed data files, with some uncertainty about what would be the final volume, once uncompressed. Alinto had to make some short notice adjustments, and they proved to be very reactive. From my end, I am really happy because it is a big move”, Thomas Lunde adds.
Full press release:
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230531005040/en/
Contact information
Additional information
Photos, logos, customer testimonials, press materials, set up of interviews on request to: Jessica Malia - Cabinet Gtec - rp@cabinet-gtec.fr - Tel. : +33(0) 4 56 40 67 26 - www.cabinet-gtec.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom